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A large proportion of human breast cancers
produce CEA (Heyderman & Neville 1977, Wahren
et al., 1978, Cove et al., 1979). Although levels in
plasma of patients with breast cancer have only a
limited use in diagnosis and monitoring progression
of the disease, (Chu & Nemoto 1973, Coombes et
al., 1980; National Institutes of Health Consensus
Development Conference Statement 1981)
measurement of CEA at the tumour level may
provide a useful marker of tumour activity in vitro.
We therefore measured CEA in media from
cultured explants of human breast cancers and
detected the marker in 75% of tumours (Miller et
al., 1980). However, these measurements give no
indication of the proportion and type of cells
producing CEA within the explants. This
information may be obtained by histochemical
staining techniques and the purpose of this study
was to compare the quantitative release of CEA
from explants into media during culture with the
results from immunoperoxidase staining for CEA.
Histologically-proven breast cancers were
obtained from 54 patients at mastectomy. Of these,
4 were classified as infiltrating lobular carcinomas
and 50 infiltrating ductal carcinomas (2 mucinous, 1
medullary and 47 showing no special features). Fifty
specimens were from the primary tumour and 4
were from invaded lymph node.
Each tumour was cut into explants measuring
4 x 1 x 1 mm. Four weighed explants were placed on
lens paper mounted on stainless-steel grids in each
of 3 petri-dishes. Waymouths 17B 725/1 medium
(2ml) containing L-glutamine (2mM), 20mM Hepes
and insulin (10jgmlP-) was added and the dishes
incubated in an atmosphere of 95%02/5%CO2 for
24h at 37°C. Culture medium was removed and
assayed for CEA by radioimmunoassay.
For radioimmunoassay, CEA was prepared from
liver secondaries of primary colonic cancer by
perchloric acid extraction (Krupey et al., 1968),
followed by chromatography on columns of DEAE-
cellulose, CM-cellulose, concanavallin A-Sepharose
and Sepharose 6B. Rabbit antiserum to the purified
CEA was absorbed extensively against perchloric
acid extracts of normal human liver, lung, spleen
and serum. Using purified CEA both as standard
and for labelling (Sturgeon, 1978), a direct double-
antibody RIA for CEA based on that of Egan et al.
(1972) was developed. The assay was standardized
using the British Standard for CEA (Laurence et al.,
1975), 1 ng of working standard being equivalent to
0.0058+0.0004 units of the British Standard.
Standard curves were prepared in culture medium.
The working range of the assays for undiluted
samples was from 3-70 ugl- l and intra-assay
precision averaged over this concentration range
was 11.4%. Inter-assay precision was 10.0%, 8.3%
and 6.4% at concentrations of 10, 25 and SOpgl-1,
respectively.
In order to assess immunohistochemical staining
for CEA, 4 explants (4 x I x 1 mm) were cut from
each tumour from the area immediately adjacent to
that used for tissue culture. The method used was
as described previously (Walker 1980). Tissue was
fixed in 4% formaldehyde in 0.15 M sodium
chloride, routinely processed and embedded in
paraffin wax. Sections were treated with 0.1%
solution of trypsin (Difco 1:250) for tOmin. Rabbit
anti-CEA serum (Dako-immunoglobulins A115),
which had been absorbed against non-specific cross-
reacting antigen, was applied followed by the 3-
stage peroxidase anti-peroxidase complex method.
Controls used were normal rabbit serum in place of
the primary antiserum; anti-CEA serum absorbed
with CEA: and positive (carcinoma of colon) and
negative (normal breast) control tissues.
Staining was assessed as negative (-ve), positive
(+ve) or + if only very occasional cells had reacted
(<5%)
Of 54 tumours, media from 41 contained
measurable amounts of CEA in all replicate cultures
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after incubation; CEA was not detected in any
culture of the remaining 13 tumours. In tumours
producing CEA, the mean level varied from 3.0-
1200ngml- 1 culture fluid. Immunohistochemical
staining for CEA gave positive results in 34 cancers.
There was no staining in the appropriate controls.
In all carcinomas which gave a reaction there were
variable numbers of +ve and -ve cells. An
example of tumour graded +ve is shown in Figure
1. The site of staining within cells was either
predominantly at the periphery with a faint
granular cytoplasmic reaction, or throughout the
cytoplasm with occasional focal intensities. All 14
tumours which were graded +ve produced CEA in
culture as did 17 of the 20 graded +ve (Table).
However, one half of the tumours which were -ve
by the immunoperoxidase method had consistently
detectable, but low levels of CEA in media after
culture (Figure 2). Concentrations of CEA produced
during culture were significantly higher (P<0.05) in
tumours graded histochemically +ve as compared
Table I Correction between immunoperoxidase and
detection of CEA in media from cultured explants
Immunoperoxidase grading
-ve +ve +ve
-ve 10 3 0
Media from
cultured explants +ve 10 17 14
X=8.75, P<0.003 trend
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Figure 1 Small groups of breast carcinoma cells, with
several individual cells having a prominent positive
reaction for CEA as diffuse or focal staining within
the cytoplasm. Immunoperoxidase, x 480.
Figure 2 CEA levels in culture media from tumours
subdivided according to immunoperoxidase grading.
Significant differences by Wilcoxon rank testing. +ve
against +ve P<0.05, +ve against -ve P<0.01.
with those in tumours graded as +ve, which in turn
were significantly higher than those graded -ve
(P<0.01).
Approximately 75% of human breast cancers
maintained in short term organ culture released
measurable amounts of CEA into the media. This
incidence is in agreement with that reported for
tumour extracts (Cove et al., 1979). From these
data, however, it is not possible to indicate which
cells or cell types are responsible for the production
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of CEA. Such information can be obtained from
histochemical studies and this study shows that
explants from 34/54 tumours investigated possessed
cells which stained positively for CEA using an
immunoperoxidase technique. The incidence of
detection of CEA by the immunoperoxidase
technique ranged in previous studies from 1.5%
(Goldenberg et al., 1978) to 83%O (Heyderman &
Neville, 1977). These variations are probably due to
the method employed and to the nature of the
antiserum. Primus et al., (1980) now advocate the
use of the peroxidase-antiperoxidase complex
method in preference to the bridge technique which
they had used previously. Like studies on other
human cancers, the present results showed that only
a proportion of the cells within the tumour explants
stained positively for CEA. The presence of CEA
staining within the cytoplasm supports its role as a
secretory product.
Only 3/34 tumours with immunoperoxidase
staining failed to release CEA into the culture
media. These 3 tumours contained very few
positively staining cells and as different explants
were used for culture, it is possible that this
discrepancy reflects heterogeneity within the
tumour.
In view of the significant positive correlation
between the immunoperoxidase technique and the
presence of radioimmunoassayable CEA in culture
media, it is likely that the cells stained
immunocytochemically are responsible for the
production of CEA during culture. Measurement of
CEA in the culture media may therefore offer a
means of monitoring the activity of these cells in
vitro.
Explants from half of the immuno-
histochemically-negative tumours released CEA into
the medium during culture. The amounts released
were relatively small and, in spite of using the
peroxidase-antiperoxidase method, it is probable
that the technique is insufficiently sensitive in
formalin-fixed paraffin embedded tissue to detect
production of small amounts of CEA. These
immunohistochemically false-negative tumours
represented 10/15 carcinomas which, while
producing CEA in culture, did so in amounts
<21igg-' tumour. This level of sensitivity for the
immunoperoxidase method would be in agreement
with that quoted by Goldenberg et al. (1978) for
similar material from other tumours. The variation
in results may also represent differences in the
nature of the antiserum used for the
immunohistochemistry and the RIA, and/or
heterogeneity within the tumour as previously
mentioned. In order to assess heterogeneity across the
tumours, sections from the paraffin blocks used
originally for histological grading were stained
immunohistochemically. Although 6/45 tumours
examined changed grading on the basis of this
larger section, only one carcinoma which released
CEA during culture but graded -ve by
histochemical staining of the explant, was classified
+ve in the tumour slice.
It is concluded that RIA of media from cultured
tumour explants provides a sensitive quantitative
estimate of CEA production by breast carcinomas,
and that immunohistochemical staining for CEA
indicates the proportion and nature of the cells
whose activity is being measured within the tumour.
It is suggested that, in order to monitor tumour in
vitro activity by CEA measurements, both methods
should be used in combination.
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